Quantitative Tc-albumin Colloid Nasal Mucociliary Clearance As an Outcome in Primary Ciliary Dyskinesia

Overview

Journal ERJ Open Res

Specialty Pulmonary Medicine

Date 2023 Sep 13

PMID 37701364

Authors

June K Marthin

Kim G Nielsen

Jann Mortensen

Affiliations

Soon will be listed here.

Abstract

Background: Primary ciliary dyskinesia (PCD) is an inherited disorder in which dyskinetic cilia cause impaired mucociliary clearance of upper and lower airways. Airway ciliary movement can be indirectly tested after administration of a radiolabelled tracer to the lower airways for assessment of pulmonary mucociliary clearance or to the nose for assessing nasal mucociliary clearance (NMC). With this study, we investigated NMC as a quantifiable study outcome parameter in patients with PCD.

Material And Methods: This single centre proof-of-concept study on NMC velocity investigated patients with PCD across different genotypes and nasal nitric oxide (nasal NO) levels. Healthy controls were used for comparison. NMC was determined as velocity in mm·min of a nasally applied Tc-albumin colloid tracer. Using a gamma camera, repeated dynamic series of images each lasting 30 s were acquired during a 10-minute period and digitally stored.

Results: NMC velocity was investigated in seven patients with PCD (aged 9-31 years) and five adult healthy controls. Mean NMC velocity in healthy controls (8.5 mm·min) was significantly higher compared with people with PCD (0.00 mm·min, p<0.0001). NMC was completely absent in all included patients with PCD across different PCD genotypes and regardless of nasal NO values. The success rate of the test was 100% in both groups.

Conclusion: NMC velocity discriminated highly significantly between patients with PCD and healthy controls. We suggest here a fast and feasible set up for NMC measurements that is easily applicable for any clinical trial involving PCD medication aimed for the nasal compartment, a step before or parallel to conducting clinical trials investigating whole-lung ciliary function in PCD.

Citing Articles

Pulmonary radioaerosol mucociliary clearance assessment: searching for genotype-specific differences and potential as an outcome measure in primary ciliary dyskinesia.

Marthin J, Holgersen M, Nielsen K, Mortensen J ERJ Open Res. 2023; 9(6).

PMID: 38076675 PMC: 10702481. DOI: 10.1183/23120541.00685-2023.

References

Lindberg S, Cervin A, Runer T . Low levels of nasal nitric oxide (NO) correlate to impaired mucociliary function in the upper airways. Acta Otolaryngol. 1997; 117(5):728-34. DOI: 10.3109/00016489709113468. View

Walker W, Young A, Bennett M, Guy M, Carroll M, Fleming J . Pulmonary radioaerosol mucociliary clearance in primary ciliary dyskinesia. Eur Respir J. 2014; 44(2):533-5. DOI: 10.1183/09031936.00011814. View

Donaldson S, Laube B, Mogayzel P, Corcoran T, Pilewski J, Ceppe A . Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study. J Cyst Fibros. 2021; 21(1):143-145. PMC: 8630086. DOI: 10.1016/j.jcf.2021.05.004. View

De Boeck K, Proesmans M, Mortelmans L, Van Billoen B, Willems T, Jorissen M . Mucociliary transport using 99mTc-albumin colloid: a reliable screening test for primary ciliary dyskinesia. Thorax. 2005; 60(5):414-7. PMC: 1758893. DOI: 10.1136/thx.2004.027680. View

Paff T, Omran H, Nielsen K, Haarman E . Current and Future Treatments in Primary Ciliary Dyskinesia. Int J Mol Sci. 2021; 22(18). PMC: 8470068. DOI: 10.3390/ijms22189834. View

Beydon N, Kouis P, Marthin J, Latzin P, Colas M, Davis S . Nasal nitric oxide measurement in children for the diagnosis of primary ciliary dyskinesia: European Respiratory Society technical standard. Eur Respir J. 2023; 61(4). DOI: 10.1183/13993003.02031-2022. View

Davis S, Rosenfeld M, Lee H, Ferkol T, Sagel S, Dell S . Primary Ciliary Dyskinesia: Longitudinal Study of Lung Disease by Ultrastructure Defect and Genotype. Am J Respir Crit Care Med. 2018; 199(2):190-198. PMC: 6353004. DOI: 10.1164/rccm.201803-0548OC. View

Davis S, Ferkol T, Rosenfeld M, Lee H, Dell S, Sagel S . Clinical features of childhood primary ciliary dyskinesia by genotype and ultrastructural phenotype. Am J Respir Crit Care Med. 2014; 191(3):316-24. PMC: 4351577. DOI: 10.1164/rccm.201409-1672OC. View

Donaldson S, Laube B, Corcoran T, Bhambhvani P, Zeman K, Ceppe A . Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR. JCI Insight. 2018; 3(24). PMC: 6338313. DOI: 10.1172/jci.insight.122695. View

10.

Walker W, Jackson C, Lackie P, Hogg C, Lucas J . Nitric oxide in primary ciliary dyskinesia. Eur Respir J. 2012; 40(4):1024-32. DOI: 10.1183/09031936.00176111. View

11.

Shoemark A, Boon M, Brochhausen C, Bukowy-Bieryllo Z, De Santi M, Goggin P . International consensus guideline for reporting transmission electron microscopy results in the diagnosis of primary ciliary dyskinesia (BEAT PCD TEM Criteria). Eur Respir J. 2020; 55(4). DOI: 10.1183/13993003.00725-2019. View

12.

Paff T, Daniels J, Weersink E, Lutter R, Vonk Noordegraaf A, Haarman E . A randomised controlled trial on the effect of inhaled hypertonic saline on quality of life in primary ciliary dyskinesia. Eur Respir J. 2017; 49(2). DOI: 10.1183/13993003.01770-2016. View

13.

Munkholm M, Nielsen K, Mortensen J . Clinical value of measurement of pulmonary radioaerosol mucociliary clearance in the work up of primary ciliary dyskinesia. EJNMMI Res. 2015; 5(1):118. PMC: 4503709. DOI: 10.1186/s13550-015-0118-y. View

14.

Wallmeier J, Nielsen K, Kuehni C, Lucas J, Leigh M, Zariwala M . Motile ciliopathies. Nat Rev Dis Primers. 2020; 6(1):77. DOI: 10.1038/s41572-020-0209-6. View

15.

Kobbernagel H, Buchvald F, Haarman E, Casaulta C, Collins S, Hogg C . Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2020; 8(5):493-505. DOI: 10.1016/S2213-2600(20)30058-8. View

16.

Marthin J, Petersen N, Skovgaard L, Nielsen K . Lung function in patients with primary ciliary dyskinesia: a cross-sectional and 3-decade longitudinal study. Am J Respir Crit Care Med. 2010; 181(11):1262-8. DOI: 10.1164/rccm.200811-1731OC. View

17.

Lucas J, Davis S, Omran H, Shoemark A . Primary ciliary dyskinesia in the genomics age. Lancet Respir Med. 2019; 8(2):202-216. DOI: 10.1016/S2213-2600(19)30374-1. View

18.

Horani A, Ferkol T . Understanding Primary Ciliary Dyskinesia and Other Ciliopathies. J Pediatr. 2020; 230:15-22.e1. PMC: 8690631. DOI: 10.1016/j.jpeds.2020.11.040. View

19.

Marthin J, Mortensen J, Pressler T, Nielsen K . Pulmonary radioaerosol mucociliary clearance in diagnosis of primary ciliary dyskinesia. Chest. 2007; 132(3):966-76. DOI: 10.1378/chest.06-2951. View

20.

Legendre M, Thouvenin G, Taytard J, Baron M, Le Bourgeois M, Tamalet A . High Nasal Nitric Oxide, Cilia Analyses, and Genotypes in a Retrospective Cohort of Children with Primary Ciliary Dyskinesia. Ann Am Thorac Soc. 2022; 19(10):1704-1712. DOI: 10.1513/AnnalsATS.202110-1175OC. View